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Opioid receptors have been demonstrated to modulate various functions
in the eye. This research was designed to determine and compare the effects of
kappa agonists on ocular hydrodynamics. Experiments were done to determine
the effects of ICI 204,448 (ICI), which is not capable of penetrating the blood-
brain barrier, and U-62066 (spiradoline) on: 1) intraocular pressure (lOP) and
pupil diameter (PD), 2) pre- (neuronal) and postjunctional sites of action, and 3)
atrial natriuretic peptide (ANP) levels in aqueous humor. Dark-adapted New
Zealand White (NZW) male, rabbits were used in all experiments. lOP (mmHg)
was measured by a pneumatonometer and PDs (mm) were measured by an
optistick before each lOP reading. Baseline readings were taken at 1/2 and 0
hours prior to drug adminstration. Post-drug measurements were made at 1/2,
1, 2, 3, 4, and 5 hours after topical drug application. The release of
norepinephrine was measured from perfused ICBs and expressed as the
percent change of the control. Cyclic AMP concentrations in the ICBs and ANP
levels in aqueous were quantified by radioimmunoassay techniques. The
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kappa antagonist, norbinaltorphimine (nor-BNI), was applied 30 minutes prior to
agonist application in all experiments. ICI and spiradoline decreased lOP in a
dose-dependent manner in normal rabbits, but only spiradoline showed
significant changes in PD. Both kappa agonist inhibited the release of NE from
perfused ICBs. Isoproterenol-stimulated cAMP levels in ICBs were lowered by
both kappa receptor agonists. ANP levels in the aqueous humor increased in
response to the kappa opioid agonists. These data suggest that spiradoline and
ICI lower lOP by activating kappa opioid receptors in the eye. The effect of
spiradoline on PD indicates that this kappa agonist activates receptors in the
eye and/or the brain. The inhibition of NE release and cAMP accumulation in
the ICB, suggests pre- and postjunctional sites of action for kappa agonists.
The increase of ANP levels in aqeous suggests a role for ANP in lowering lOP.
If these drugs can be shown to lower lOP safely and effectively in humans, then
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Glaucoma is the leading cause of blindness in the United States. It is
estimated that by the year 2000, 66.8 million people will be affected, and 6.7
million of those will be blind in both eyes (Quigley, 1996). Glaucoma comes
without warning, like a thief in the night. A buildup of fluid in the anterior
segment of the eye causes increased intraocular pressure (lOP) that is
transmitted throughout the globe and damages the optic nerve, the most
vulnerable point in the eye. Because the optic nerve is responsible for sending
visual images from the retina to the brain, damage to the optic nerve head
usually occurs gradually, but the deleterious effects on visual function are
permanent. Although glaucoma usually damages both eyes, it often begins by
affecting one eye first. Visual loss typically begins with loss of peripheral vision
first, followed by a loss in central vision and then, potentially, blindness.
Elevated lOP is one of the risk factors in open-angle glaucoma that can
be controlled by medical and/or surgical therapy. Drug therapy has proven to be
an effective treatment for lowering intraocular pressure in glaucomatous
patients. If identified early and managed properly, the visual damage caused
by this disease can be controlled, resulting in a majority of patients retaining
visual function for an extended period. There are a variety of drugs available for
the treatment of glaucoma, but the treatment is predicated on an individual’s
response to a therapeutic regimen consisting of one or more drugs or surgery.
Some drugs are not effective in certain patients, whereas other drugs may
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cause significant side effects, at this point surgical procedures are implemented.
Although combinations of drugs can also be used effectively, more efficacious
drugs are being sought. Currently, drugs that have the capability to enhance
outflow facility, produce neuroprotection and/or induce positive effects on the
blood flow to the optic nerve head are preferred. These properties, along with
the general characteristic of lowering lOP with minimal side effects, could lead
to the development of improved glaucoma therapies.
This research project was designed to identify the mechanisms of action
of a specific class of opioid agonist. The primary objective of this research was
to determine and compare the effects of two kappa opioid receptor agonists,
one that is capable of penetrating the blood-brain barrier and one that is not, on
the hydrodynamics in the anterior chamber of the eye. The rationale behind this
project is that the research will enhance the knowledge of the role of the kappa
opioid receptors in the eye and elucidate the mechanisms by which these
opioid agonists modulate ocular hydrodynamics. The results of these studies
could lead to a novel treatment that could limit the damage (optic nerve
dysfunction and visual field defects) caused by increased lOP.
The multiple hypotheses to be tested by this research were that: 1) kappa
opioid receptors modulate aqueous humor dynamics; 2) the effects are
mediated by actions at prejunctional and postjunctional sites in the iris ciliary
body: and 3) lowering of lOP is mediated, in part, by the increased release of
the neuropeptide, atrial natriuretic peptide in aqueous humor. To test these
hypotheses, ICI 204,448 (ICI) and U-62066 (spiradoline), relatively selective
kappa receptor agonists, were examined alone or together with the antagonist,
nor-binaltorphimine (nor-BNI), for the effects on lOP, sympathetic neuronal
function, second-messenger systems, and neuropeptide release. It is believed
from previous work (Wang and Potter, 1996) that ocular hydrodynamics can be
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modulated not only by agonist action at opioid receptors in the brain, but also by
interaction with peripheral opioid receptors in the eye. ICI 204,448 is a kappa
opioid agonist with limited access to the central nervous system (CNS) (Shaw,
1989). ICI was used in this study as the tool used to determine if peripheral
kappa receptors of the eye are responsible for inducing alterations in ocular
hydrodynamics. The studies using ICI included measuring lOP and pupil
diameter (PD) and were compared with the results of spiradoline, another
selective kappa receptor agonist. Spiradoline has been shown to cause
cardiovascular depression when administered by intravenous injection,
showing that it is capable of crossing the blood-brain barrier (Hall, 1988).
In preliminary studies, ICI was shown to cause a dose-dependent
reduction of lOP. However, ICI showed no significant effects on pupil diameter.
This factor may prove to be a point of comparison in the actions of ICI and
spiradoline. For example, alteration of PD could be either an effect on CNS
receptors or on receptors that are present within the iris. Spiradoline, which is
capable of widespread distribution, should not only lower lOP, but also cause
miosis. Previously, it has been shown that a variety of opioids cause miosis in
humans, dogs, and rabbits (Murray, R. B., 1983) but may cause mydriasis in
some species.
The previous work and the related hypotheses led to the proposal of the
following specific aims:
1. To characterize and compare the activities of kappa agonist, ICI
204,448 hydrochloride and U-62066 (spiradoline mesylate), in modifying the
intraocular pressure and pupil diameter in the presence and absence of the
highly selective kappa antagonist, nor-binaltorphimine, in normal rabbits.
2. To investigate the pre- (neuronal) and postjunctional (ciliary body)
sites of spiradoline and ICI.
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3. To determine if kappa receptor agonists can affect other





Glaucoma is a multifactorial disease that is the world's leading cause of
irreversible blindness. Glaucoma is defined as a group of eye diseases that is
usually characterized by an increase in intraocular pressure (lOP), which
causes pathological changes in the optic nerve head and progressive defects in
the field of vision. Most forms of the disease progress painlessly, and the vision
loss is insidious (Alward, 1998). There are three major categories of glaucoma:
congenital, open-angle, and angle-closure. These latter categories are so
named because of the nature of obstruction to aqueous humor outflow. The
glaucomas can also be divided into primary and secondary subtypes. The most
common type of glaucoma in the United States, particularly in the African-
American community, is primary, open-angle glaucoma (POAG) (Leske, 1983).
Primary, angle-closure glaucoma is the second most common type and is more
prevalent among Asians. The secondary glaucomas occur less commonly
whereas the congenital type of glaucomas are relatively rare.
Primary open angle glaucoma is caused by restricted outflow of the
aqueous humor. Aqueous humor is formed in the posterior chamber by the
epithelial layer of the ciliary body. Once formed, it flows from the posterior
chamber into the anterior chamber via the opening in the iris (pupil). A constant
flow of aqueous humor is necessary for structural integrity and normal optical
functioning of the eye. Aqueous humor provides flow of substrates to avascular
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tissues of the eye (cornea, lens) and removes waste products. In order to
maintain this equilibrium, as new aqueous humor is formed and passed through
the pupil, the existing aqueous humor is continuously drained from the anterior
chamber through the outflow tracts into the venous system. The aqueous
humor can exit the anterior chamber by two routes. The first (direct) outflow
pathway is through the trabecular meshwork into the canal of Schlemm, which
is positioned within the iridocorneal angle. From the canal of Schlemm, the
humor drains into the intracleral and episcleral venous plexus. The indirect
(uveoscleral) pathway begins with the aqueous humor passing into the tissues
of the ciliary body, then flowing through the interstitial spaces of ciliary muscle
and choroid known as the suprachoroidal space. Aqueous humor then flows
through the vascular channels of the sclera into the connective tissue of the
orbit, where it probably drains from the veins into general circulation.
Uveoscleral drainage accounts for less than 20% of the total drainage in normal
humans (Bill, 1971), but becomes a more critical factor when conventional
(trabecular) outflow becomes impaired in glaucomatous subjects. In open-
angle glaucoma, the cause(s) of increased outflow resistance is not as easily
determined as that of angle-closure glaucoma, where the iridocorneal angle
actually becomes more narrow to the point of occlusion (see left panal of Figure
1). The iridocorneal angle in POAG usually remains adequate, but filtration is
gradually diminished because of changes in the trabecular tissues located in
the angle. Because the disease process is relatively insidious, awareness of
the risk factors and eye exams are recommended routinely for persons over the
age of 35.
The four major risk factors for primary open-angle glaucoma are
advanced age, black race, family history, and elevated lOP (Alward, 1998).
Most studies that have compared the relationship between age and POAG have
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confirmed that the prevalence of glaucoma is greater in older individuals (The
Glaucomas, 1996). In a study by Tielsch et al., the rates of definitive POAG rose
with increasing age, with a two-fold to 10-fold increase for persons aged 80
years or older as compared with those between the ages of 40 and 49. The
study showed that African Americans have higher rates of POAG than
Caucasians at every age. The finding of race as a major risk factor for POAG is
based on data indicating a higher prevalence of the disease among Blacks
(Mason, 1989; Tielsch, 1991). These data support the second risk factor, that of
being of the black race increases the probability of developing glaucoma. The
higher risk of POAG among Blacks probably reflects an underlying genetic
susceptibility to this disease. Family history or heredity has been implicated in
several ocular parameters associated with glaucoma. The final risk factor,
elevated lOP, is the one that can be manipulated. In POAG, elevated lOP is
usually a result of an increase in outflow resistance (see right panal of Figure 1).
Elevated lOP, as stated earlier, can cause damaging changes (cupping) to the
optic nerve head. A reduction of lOP can slow the progression of further




Figure 1. The site of obstruction of aqueous humor outflow in angle-closure and
open-angle glaucoma. The site of obstruction in angle-closure (A) and in open-
angle glaucoma where the obstruction is within the trabecular meshwork
preventing access to the Canal of Schlemm (B) (Schwartz, 1978).
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Thus, glaucoma is an optic neuropathy in which the supporting plates of
the optic nerve head (lamina cribrosa) collapse and the larger axons of the optic
nerve die, leading to loss of optic nerve tissue and excavation, or "cupping" of
the optic nerve head. As axonal loss occurs, peripheral vision begins to slowly
decline, eventually leading to the loss of visual fields (Alward, 1998). Because
there is no cure for glaucoma, treatment is focused on either lowering lOP by
using drugs or performing surgery to create another outflow pathway
(trabeculectomy orfiltration surgery). Intraocular pressure reduction by drugs is
accomplished either by decreasing the amount of aqueous humor being formed
or by increasing its outflow through either the trabecular or uveoscleral outflow
tracts. Treatment of POAG usually begins with the topical application of drugs.
This therapy includes drugs from various classes such as p-adrenergic
antagonists, prostaglandins, a2-adrenergic agonists, or carbonic anhydrase
inhibitors (Alward, 1998; Mishima, 1996). Other classes of drugs that may have
potential for glaucoma therapy are now being investigated. These classes
include drugs such as cannabinoids (Green, 1982; Hepler, 1971) and opioids
(Wang, 1996). When a drug, used alone or in combination with other drugs,
becomes inefficient in controlling lOP, more drastic therapeutic measures, i.e.,
surgery, have to be taken in order to maintain normal pressure and prevent
further damage. Thus, alternative therapy involves surgically increasing
aqueous outflow by either creating an auxiliary egress route for aqueous or by
increasing facility of outflow utilizing laser trabeculoplasty.
Opioids and Opioid Receptors
Morphine was the first natural opiate to be identified and characterized in
1805 by a German chemist, Friedrich Serturner. It was isolated as one of the
analgesic components of opium, a product of the poppy. Morphine and other
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naturally occurring opiates possess dramatic effects on the mammalian nervous
system but have addictive properties. In the mid- 1970’s, opiate-like activity was
found in the porcine brain and were subsequently characterized (Hughes,1975). These endogenous peptides were determined to be methionine- and
leucine-enkephalins. Subsequently, two additional peptides were isolated and
characterized from the hypothalamus, that were structurally similar to leu-
enkephalin at the N terminus and were named a- and p-neoendorphin. A third
class of opioid peptides, the dynorphins, was identified as a pituitary peptide
with opiate-like activity on the guinea pig ileum (Cox, 1975).
Opiates and endogenous opioid peptides affect organ systems that
regulate the body’s responses to stress and are known to exert these affects on
target tissues through binding to cell surface receptors. By using radiolabeled
opioid ligands, several investigators have demonstrated the presence of opioid
receptors in the brain (Pert and Snyder, 1973; Simon, 1973; Terenius, 1973)
and other organs. Martin and colleagues (Martin 1976; Gilbert and Martin,
1976) proposed that there were three types of opioid receptors, mu (|i) for the
morphine group, kappa (k) for the ketocyclazocine group, and sigma (o) for N-
allylnormetazocine group. In addition to these three classes of opioid receptors,
a receptor was found with a high affinity for enkephalins and was named the
delta (6) receptor (Lord, 1977). The a receptor has been shown to be non¬
opioid in nature, thereby leaving three main types of opioid receptors
(Mannalack, 1986). Evans et al. (92) and Kieffer et al. (92) identified the
structure of the 5-opioid receptor, and thereafter the cDNAs of the p.- and k-
opioid receptors were cloned (Chen, 1993; Yasuda, 1993). The cloned amino
acid sequences of the opioid receptors have indicated that these receptors
have seven putative transmembrane helices characteristic of the G-protein
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coupled receptor family. The amino acid sequences of p, k, and 6 receptors are
approximately 60% identical to one another (Figure 2).
The p-opioid receptors are further classified into pi- and p2-subtypes.
These subtypes have varying affinities for mu agonists, morphine and [D-
Ala^.N-Me-Phe'^, Gly-o|5]-enkephalin (DAMGO), and the selective antagonist
CTAP. The delta receptor has high affinity for the agonists [D-Ala^.D-Leu^]-
enkephalin (DADLE) and [D-Pen2.5] enkephalin (DPDPE), and naltrindole, the
delta receptor antagonist. The k receptor has high affinity for dynorphin A, an
endogenous kappa opioid agonist, and other ligands such as spiradoline
mesylate and ICI 204,448 hydrochloride. See Table 1 for additional p- S-, and
K-opioid receptor agonists and antagonists.
The orphan receptor (ORL) was identified in rat, mouse and man,
with a 90% degree of homology among the species. The ORL receptor has
been accepted as a member of the opioid receptor family on the basis of its
structural homology towards the three known types, but there is no
corresponding pharmacological homology. Non-selective ligands that have
uniformly high affinity for p-, k-, and 6-receptors, have very low affinity towards
the ORL receptor. There are very few known highly selective agonists for this
receptor (Table 1). There is evidence of additional types of opioid receptors, the
epsilon receptor (e, Wuster, 1979), the zeta receptor (^, Zagon, 1991), found in
the cornea, and the lambda receptor (A,, Grevel, 1985).
The opioidergic system is relatively inactive under normal physiological
conditions but can be activated by a variety of stressors. Aerobic exercise has
been shown to be an activator of the opioidergic pathways within the central
nervous system (Hoffman, 1996). Therefore, if this opioidergic system can be
shown to effectively lower intraocular pressure, exercise and/or acupuncture
may, in some way, be utilized in conjunction with pharmacotherapy in those
diagnosed with glaucoma.
Figure 2. Putative transmembrane topology of the cloned delta-opioid receptor(DOR). Each amino acid residue is represented by a circle, where the white
circles indicate amino acids that differ between DOR, the cloned mu receptor(MOR), and the cloned kappa receptor (KOR). Gray circles show residues that
are conserved in two of the three receptors and black circles indicate amino
acids that are identical in all three (Stein,ed., 1999).
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Table 1. Selective opioid ligands^(Corbett, 1999).
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Ocular Actions of Opioids
Opioid receptors are present not only in the central nervous system but
also in a variety of peripheral organs. Evidence for the presence of these
receptors in the iris was shown by analyzing the effects of the local
administration of agonist and antagonists on the pupil in New Zealand albino
rabbits (Drago, 1980). Opioids have an affect on different parameters within the
eye such as iris function, aqueous humor dynamics, lacrimal secretion, and
proliferation of the corneal epithelium. With regards to iris function, the change
in pupillary size induced by opioids has been shown to be species dependent.
In humans, dogs, and rabbits miosis (pupil constriction) occurs, whereas in
monkeys, cats, rats, and mice mydriasis (pupil dilation) follows the
administration of opioids by various routes (Murray, 1983). It is believed that
the constricting effect on the iris is mediated through an action in the central
nervous system, but some researchers suggest that miosis is caused by
stimulation of opioid receptors located on the iris sphincter (Nomof, 1968;
Drago, 1980).
Despite the method of administration, opioids appear to lower intraocular
pressure (lOP). Intraocular pressure in rabbits was lowered by heroin (Green,
1975) and also by morphine hydrobromide when administered intravenously
(Uusitalo, 1972). This opioidergic decrease in lOP is also observed in humans.
Morphine sulfate, given intramuscularly, decreased lOP in normal patients and
in those diagnosed with glaucoma (Leopold, 1948). In a study that investigated
the effects of the mu receptor agonist, heroin, aqueous outflow facility was
shown to increase by 50% in the rabbit (Green, 1975). Recent studies from our
laboratory indicate that bremazocine, a relatively selective kappa receptor
agonist, lowers the inflow of aqueous humor in rabbits (Russell, 1999). These
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studies suggest that separate opioidergic receptors may mediate the inflow
(secretion) and outflow of aqueous from the anterior chamber of the rabbit eye.
Pre- and Postjunctional Actions of Opioids
Opioid agonists regulate the release of neurotransmitters in the central
and peripheral nervous systems by activating presynaptic opioid receptors.
Although the predominant effect of opioids is to inhibit the release of
neurotransmitters (Jhamandas 1977; Werling 1987), there is also evidence of
the enhancement of release (Oron, 1991; Suarez-Roca, 1993). The inhibitory
effect on neurons is thought to be exerted via membrane hyperpolarization
(North 1983; North 1986; Wuarin 1988; Serafin, 1990) or the shortening of
action potential duration (Werz, 1983; Shen, 1989). These cellular events have
been attributed to activation of an inwardly rectifying potassium conductance
(Williams, 1984; Grudt, 1993) and/or to inhibition of voltage-activated calcium
channels (Gross, 1987; Schroeder, 1991; Akins, 1993). The mu and delta
opioid subtype receptors were found to be coupled to potassium channels
(North, 1987), and all three (|i, 5, and k) receptors were demonstrated to be
linked to voltage-activated calcium channels (Attali, 1989; Henderson, 1990;
Hescheler, 1987). Another cellular component that may mediate the inhibitory
regulation of neurotransmitter release is suppression of adenylate cyclase
activity. The opioid subtypes have all been shown to inhibit cAMP production in
a variety of tissues (Attali, 1989; Yu, 1986). It is possible that the inhibitory effect
of opioids on neurotransmitters is mediated by an admixture of various cellular
mechanisms. Other evidence suggests that there is heterogeneity in the opioid
receptors that regulate norepinephrine (NE) release (Kim, 1993), and this could
indicate that each receptor may induce inhibition by different combinations of
mechanisms.
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Opioids have been shown to inhibit the stimulated release of tritiated-
norepinephrine (^H-NE) from cerebral cortex slices of the rat (Montel, 1974),
guinea pig (Werling, 1987), and rabbit (Limberger, 1986). Depression of
electrically stimulated NE release by opioid receptor agonists were also
demonstrated in peripheral tissues such as the mouse vas deferens
(Henderson, 1972), cat nictitating membrane (Dubocovich, 1980), and cat
spleen (Gaddis, 1982). Previous studies from this laboratory suggest that delta
opioid agonists inhibit stimulated ^H-NE release in rabbit ICB (Wang, 1996). It
has been shown that the rabbit ICB contains functional, prejunctional alpha-2
adrenoceptors (Jumblatt, 1987) and agonists of this receptor have been shown
to lower lOP (Potter, 1984; Jumblatt, 1993). If this is the case, it is possible that
rabbit ICB may have prejunctional kappa opioid receptors that modulate NE
release thereby lowering intraocular pressure.
As stated above, opioid receptors of all classes have been shown to be
negatively coupled to adenylate cyclase. This mechanism is an example of a
signal transduction pathway found in many tissues and is considered to be a
predominantly postjunctional index of activity. Interest in this study was focused
on one classic and well-characterized second messenger - cAMP. Opioids and
cAMP production have been studied extensively in a variety of tissues, and all
three types of opioid receptors have been shown to inhibit adenylate cyclase
(Childers, 1991) causing decreased levels of cAMP. More specifically, kappa-
inhibited adenylate cyclase has been reported in rat spinal cord neurons (Attali,
1989) and guinea pig cerebellum (Konkoy, 1989). There is evidence that some
of the biological responses linked to opioid receptors and adenylate cyclase are
dependent on a pertussis toxin (PTX) sensitive guanine nucleotide-binding
(G|/o) protein (Kurose, 1982). For example, the kappa receptor has been linked
to adenylate cyclase by a PTX-sensitive inhibitory guanine nucleotide-binding
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(G|) protein in the mouse thymoma cell line (Lawrence, 1993). The effect of
opioids on the modulation of cGMP seems to be opposite to the effect that they
have on cAMP. Experiments have shown that opioids increase levels of cGMP
in cells and brain slices (Pasternak, ed.). The molecular properties of the
receptor-coupled guanylate cyclase are less well defined than those of
adenylate cyclase, although the two systems are very similar. One important
difference that exists between these structurally similar cyclase systems is that
guanylate cyclase exists in both membrane-associated and soluble forms in
mammalian systems. The atrial natriuretic peptide (ANP) receptors are
structures that have been shown to be linked to guanylate cyclase (Garbers,
1992; Levin, 1993; Nakane, 1994). As described later, opioid agonists have
been demonstrated to release ANP in the kidney and the eye.
Atrial Natriuretic Peptide
Atrial natriuretic peptide (ANP) is a 28 amino acid peptide that is primarily
synthesized in the heart. ANP is in a family of three known natriuretic peptides
that include brain natriuretic peptide (BNP) and C-type natriuretic peptide
(CNP). ANP and BNP are both made in and secreted from the heart, circulate in
plasma, and have many of the same biological functions (Cao, 1995). These
functions include causing changes in fluid and electrolyte metabolism and
blood pressure homeostasis (Suga, 1992). CNP is made primarily in non¬
cardiac tissues, does not circulate at appreciable levels in plasma and has a
different activity profile at the level of target tissues (Cao, 1995). All three
peptides are involved in natriuresis and diuresis.
ANP has been shown to have effects on several peripheral organs, such
as the kidney and the eye; it has vasorelaxant activity in vascular smooth
muscle. Atrial natriuretic peptide also has antimitogenic activity in renal
17
mesangial cells, vascular smooth muscle, and endothelial cells (Cao, 1995).
Several publications have documented that ANP has effects in the eye. For
example, ANP has been documented to lower lOP in rabbit eye, (Sugrue, 1986;
Nathanson, 1987; Mittag, 1987; Korenfeld, 1989) and similar hypotensive
effects have been reported in humans (Diestelhorst, 1989; Wolfensberger,
1994). ANP is present in the aqueous humor of rabbits (Fernandez-Durango,
1991) and has been suggested to be involved in the control of aqueous humor
formation in monkeys (Samuelsson-Almen, 1991).
There are three natriuretic peptides receptors (NPR) that interact with the
natriuretic peptides. The NPRs are identified as NPR-A, NPR-B, and NPR-C.
ANP and BNP have a high affinity for NPR-A, whereas CNP only has affinity for
the B type receptor. NPR-C has demonstrated binding capabilities to all three
peptides and functions to clear the peptides from circulation (Maack, 1987;
Fuller, 1988). All three receptors have been identified in the ciliary processes of
the eye of rats and rabbits (Bianchi, 1986; Coca-Prados, 1999). NPRs have
also been found on human trabecular meshwork cells (Chang, 1995), and
ciliary body epithelial cells (Crook, 1997).
ANP exerts its effects, in part, via receptor-mediated synthesis of the
second messenger, cGMP (Figure 3). ANP has been shown to stimulate
guanylate cyclase derived from membranes of ciliary processes (Mittag, 1987)
and guanylate cyclase was isolated on the cytoplasmic domain of the amino
acid transmembrane protein sequence of NPR-A and NPR-B in cloning studies
(Chang, 1995). Receptors have been found on the epithelial side of the ciliary
body and were shown to be negatively coupled to adenylate cyclase (Bianchi,
1986). Thus, it may be that ANP stimulates cGMP formation but inhibits cAMP
synthesis in the eye.
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Studies have demonstrated that opioid peptides stimulate the release of
ANP from the kidneys of animals (Stasch, 1989; Gutkowska, 1986; Xie, 1988).
However, under normal conditions, endogenous opioid peptides do not affect
ANP release in humans (Borges, 1988; Kidd, 1987; Fontana, 1993). In contrast,
p-endorphin, an endogenous |i-receptor antagonist, has been shown to
influence ANP release during strenuous exercise in man (Louisy, 1989).
Morphine (a mu-receptor agonist) increased plasma levels of ANP when
administered intravenously or intracerebroventricularly in low doses and the
effects were reversed by naloxone, an opioid antagonist (Gutkowska, 1986).
This latter study also showed that basal levels of ANP were decreased by
naloxone, implicating the role of endogenous opioids on ANP regulation.
Some researchers believe that the inhibitory effect of morphine and other p-
receptor agonists may occur secondarily to the hemodynamic changes that
morphine may induce. In another study, morphine had no stimulatory effect on
the release of ANP from isolated atria (Stasch, 1989). In atrial cardiocytes,
DAGO (p-opioid), met-enkephalin (py5-opioid), nor DADLE (5-opioid) stimulated
the secretion of ANP in atrial cardiocytes (Yamada, 1991; Lachance, 1986). On
the other hand, dynorphin and spiradoline significantly stimulated the secretion
of ANP in isolated atria, and effects of both were suppressed by a kappa
antagonist, indicating activation through K-opioid receptors (Yamada, 1991).
These prior studies were the basis for evaluating the effects of spiradoline and
ICI 204,448 on ANP release in the eye.
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New Zealand White (NZW) male rabbits (2-4 kg body weight) were used
for all in vivo and in vitro experimental procedures. The rabbits were purchased
from Myrtle Babbitry, Thompson Station, Tennessee. They were maintained in
a temperature-regulated room and were dark adapted. Dark adaptation refers
to a 12 hour reversed dark/light cycle. All rabbits were housed individually and
the care and treatment were conducted in accordance with the National Institute
of Health (NIH) and Association for Research in Vision and Opthalmology
(ARVO) regulations on the care and use of animals for research. All protocols
were approved by the Institutional Animal Care and Use Committee of
Morehouse School of Medicine.
Drugs
The drugs chosen for these experiments were based on their general
physicochemical characteristics and assumptions of their pharmacologic
actions. ICI 204,448 (R, S-N-[2-{methyl-3,4-dichlorophenylacetamido}-2-{3-
carboxyphenyl}-ethly] pyrrolidine hydrochloride) is a kappa opioid receptor
agonist which has been demonstrated to exhibit high relative selectivity towards
kappa receptors but low penetrability of the pial-glial barrier (Shaw, 1989). U-
62066 (spiradoline mesylate) is another opioid that is highly selective for the
kappa receptor. Spiradoline has been shown to cause cardiovascular
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depression when administered by intravenous injection, showing that, unlike
ICI, it is capable of crossing the blood-brain barrier (Hall, 1988). The antagonist
chosen for this study was nor-binaltorphimine dihydrochloride (nor-BNI), which
is a highly selective kappa opioid receptor antagonist (Portoghese, 1987). See
Figure 4 for the chemical structures of these drugs.
Drug solutions were made using appropriate vehicles. Distilled water
was used in preparing experimental solutions for spiradoline and nor-BNI. ICI
was dissolved in 45% w/v 2-hydroxypropyl-B-cyclodextrin. All solutions were
made on the day of the experiment. Topical administration was utilized in in
vivo experiments because it is an effective route to reach structures within the
anterior segment of the eye. In lOP experiments, the agonists were applied
topically and unilaterally in 25pl volumes to the cornea. The appropriate
vehicle was applied to the contralateral eye. In experiments to determine kappa
opioid receptor involvement, the antagonist nor-BNI was applied topically and
bilaterally 30 minutes prior to a challenge with the kappa agonist. The drug
administration in these lOP experiments was performed in a masked design,
i.e., the person performing the lOP measurements had no prior knowledge of
the solutions’ contents.
Intraocular Pressure (lOP) and Pupil Diameter (PD) Measurements
NZW rabbits were maintained on a dark/ light cycle, i.e., were dark-
adapted. The reversed light cycle and measurement of lOP under darkroom
conditions maximizes sympathetic tone in the rabbits and results in elevated
lOP levels (Rowland, 1981). Prior to each lOP determination, the corneas were
anaesthetized with 25 |il tetracaine hydrochloride (0.5%) to minimize
discomfort. lOP was measured in mmHg using a manometrically calibrated
applanation pneumatonometer, Digilab Inc., Division of Bio-Rad (Cambridge,
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MA). Pupil diameters (PD) were measured in millimeters (mm) by an optistick
before each lOP reading. Baseline lOP and PD readings were taken at 1/2 and
0 hours prior to drug administration. Post drug measurements were made at
1/2, 1, 2, 3, 4, and 5 hours after drug application. If drug effects persisted
beyond 5 hours, additional measurements were made until recovery occurred.
In control animals, the vehicle was applied to both eyes at time 0 hour with the




K-opioid receptor agonist that does not cross the blood brain barrier.
SPIRADOLINE MESYLATE
A highly selective k opioid receptor agonist.
r<l I>^
nor-BINALTORPHIMINE DIHYDROCHLORIDE
A highly selective k opioid receptor antagonist.
Figure 4. Chemical structures of kappa agonists and antagonist.
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3H - NE Overflow in Rabbit Iris-Ciliary Body
In these experiments, rabbit iris ciliary body (ICB) preparations were
perfused with physiological salt solutions containing increasing concentrations
of a kappa agonist (10-^ to 10-5 M) to investigate ^H-NE overflow in vitro in
response to electrical field stimulation. To surgically isolate the ICB, NZW male
rabbits were euthanized by air immobilization and the eyes were enucleated.
Dissection of the eye took place in oxygenated saline in a small petri dish. The
ICB was removed and cut into three or four pieces of similar sizes. The ICB
pieces were incubated for an hour at 37° C in a oxygenated bicarbonate-rich
and HEPES-buffered solution (NaCI, 115 mM; KCI, 5 mM; CaCl2, 1.8 mM;
MgS04, 0.8 mM; NaH2P04, 0.9 mM; NaHCOa, 26 mM; glucose, 10 mM; HEPES,
10 mM; indomethacin 2.2 mg%, pH 7.4) containing 2.5 p.Ci/ml ^H-NE. After the
preliminary incubation, ICB pieces were transferred to temperature-controlled
(370 C) plexiglass superfusion chambers containing built-in electrodes and
superfused at a rate of 2 ml/min with normal Ringer’s solution containing 1 p.M
desipramine to block reuptake of NE. During superfusion, the tissues were
subjected to periodic electrical field stimulation (12 V/cm, 5 Hz, 1 min).
Between and during periods of electrical stimulation, fractions (2 ml) of
the superfusate were collected at 1 minute intervals and analyzed for
radioactivity. From these fractions, 0.5 ml samples were counted in a liquid
scintillation counter and reported as disintegration per minutes (dpm) per
fraction. Results have demonstrated that, under control conditions, the
quantities of ^H-NE released during consecutive stimulation periods (SI
through S5) were of the similar magnitude. In an ICB preparation run in
parallel, doses of ICI or spiradoline were dissolved in the same buffer solution
and given on a cumulative bases in a series of three doses (lO-^, 10-6, and lO'^
M). Prior to and subsequent to each dose of the agonist, tissues were
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stimulated electrically to release NE from sympathetic nerve endings. In other
experiments, ICI or spiradoline’s effects were studied after the addition of nor-
BNI (10-5 M), a kappa antagonist. The changes in NE overflow were expressed
as the percent change from control stimulation (S1) as calculated from areas
under the curves (S2/S1, S3/S1, etc.).
cAMP Measurement
NZW male rabbits were euthanized as described previously, and their
eyes were enucleated. The eyes were immediately placed in saline on ice until
dissected. During the dissection, the eye was opened to expose the posterior
segment. Then, the vitreous humor, lens, and excess portions of the globe were
removed with scissors and forceps. The ICB was carefully detached and placed
in a saline-filled petri dish where it was cut into six pieces of similar size. Using
six well plates, one piece of tissue was placed in each well and incubated for
thirty minute in 2 ml of 2.2 mg% indomethacin in a physiological solution to
inhibit prostaglandin formation. Incubations were carried out in a humidified
incubator gassed with 95% O2 and 5% CO2. The tissues were treated with lO'^
M 3-isobutyl-1-methyl-xanthine (IBMX), a nonselective phosphodiesterase
inhibitor, to prevent degradation of cAMP and then incubated for an additional
10 minutes. The beta adrenoceptor agonist, isoproterenol (ISO, 10-® M), was
used to stimulate adenylate cyclase and raise cAMP levels. The kappa receptor
agonist (lO-^ tolO'^ M) and ISO were added sequentially to the tissue at 10
minute intervals in the presence or absence of the specific kappa receptor
antagonist (nor-BNI, lO’^ M). The pretreatment with the antagonist preceded
the exposure to the kappa agonist and ISO by 30 mins. All experiments were
conducted in duplicate and repeated at least four times.
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After completion of the treatment procedures, tissues were quickly
removed and placed into microfuge tubes then frozen by immersion in liquid
nitrogen. The frozen tissue was stored at -80° C for later analysis. The frozen
samples were homogenized in 300 pi of 10% trichloroacetic acid (TCA) at 4° C.
The homogenates were centrifuged at 2,000 g for 10 minutes and 175 pi of the
supernatant were removed for determination of cAMP levels using a
radioimmunoassay (RIA) kit supplied by Amersham. Protein concentrations
were determined by a Bio-Rad assay using 300 pi of IN NaOH solution that
was added to the remaining pellets. The concentrations of cAMP were
determined from the standard curve and expressed as pmol / mg protein.
Radioimmunoassay (RIA) for Atriai Natriuretic Peptide
The rabbits’ eyes were treated with the kappa agonist 30 minutes prior to
removal of the aqueous humor (AH) by paracentesis. The effects of ICI and
spiradoline on ANP levels in the AH was measured by RIA. After the rabbit had
been euthanized, paracentesis was used to obtain -100 to 150 pi of aqueous
humor from the anterior chamber of the rabbit eye. The aqueous was
immediately placed in an iced test tube containing aprotinin, a proteinase
inhibitor. The concentration of ANP in the AH was determined by RIA utilizing a
kit obtained from the Peninsula Laboratories. This double antibody assay
required two overnight incubations. Initially, the primary antibody plus the
aqueous humor aliquot necessitated a 16-24 hour incubation period at 4 OC.
The second incubation was provided to allow competitive binding time for the
tracer (125|.anP) with the unbound peptide. Upon the completion of the
incubations and the addition of the second (precipitating) antibody, the samples
were separated by centrifuging and read in a gamma counter. The amount of
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ANP in the aqueous humor was determined from a standard curve and the ANP
levels expressed as pg / ml.
Statistical Analysis
The statistical analysis of experimental data utilized the Student’s t-test
assuming equal variances. Values were reported as the mean ± SE. The level
of significance chosen was p < 0.05.
CHAPTER IV
RESULTS
Intraocular Pressure and Pupil Diameter Experiments
Intraocular pressure was measured in normal, male, dark-adapted NZW
rabbits. The drugs were administered topically and unilaterally. The effect of
spiradoline on lOP was measured in a dose-response manner. Three doses
(1, 10, and 100 ng / 25 nl) were graphed against the control. Figure 5 shows the
dose-dependent effects of spiradoline in the ipsilateral (drug-treated) eye. A
significant decrease in lOP was observed at one hour post drug administration
(10 and 100 ng / 25 nl) and the responses lasted for up to four hours (100 jig / 25
nl) in the ipsilateral eye. The contralateral (vehicle-treated) eye displayed a
significant decrease in lOP only with 100 ng (Figure 6).
Pupil diameter was also measured at these doses. Spiradoline had a
transient miotic effect on PD in both the ipsilateral and contralateral eyes. The
change occurred 1/2 and one hour post application in the ipsilateral eye (Figure
7) and at 1/2 hour in the contralateral eye (Figure 8).
ICI, a predominantly peripherally acting kappa agonist, also caused a
dose-dependent (25 |ig, 50 ^g, and 100 |ig / 25 |il) reduction of lOP. A
significant bilateral decrease in lOP was seen as early as a 1/2 hour after the
administration of the highest dose (100 ^ig) of ICI (Figure 9). This decrease in
lOP in the ipsilateral eye was observed with 100 ^g and lasted as long as five
hours with gradual recovery toward the control. The response was maximal
(~6-7 mmHg) for one to three hours. In the contralateral eye, there was a
significant decrease in lOP that began 1/2 hour after drug application (Figure
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10), but the depression of lOP gradually returned to basal levels after two hours.
The lOP response in the ipsilateral eye was slightly greater than the response in
the contralateral eye. There was no significant change in PD in either the
ipsilateral or contralateral eye after application of ICI (Figures 11 and 12).
Bilateral pretreatment with the kappa opioid receptor antagonist, norBNl
(200 |i,g / 25 p.1), inhibited the reduction of lOP by spiradoline in the ipsilateral
eye (Figure 13). The greatest reduction of lOP (~4 mmHg) with spiradoline was
observed with the concentration 100 ^g, therefore this concentration was used
to show the antagonistic effects of norBNl. With the same concentration of
spiradoline, the contralateral eye had a similar decrease in lOP. This decrease
of lOP was totally antagonized by norBNl (Figure 14). The transient effect of
spiradoline on PD was antagonized by norBNl in both the ipsilateral (Figure
15) and contralateral eyes (Figure 16).
ICI elicited a greater decrease in lOP (~7 mmHg) in the ipsilateral eye
when compared to the response to spiradoline (~4 mmHg). The antagonistic
effects of norBNl were also greater. The kappa antagonist, norBNl, significantly
inhibited the decrease in lOP by ICI (Figure 17) and its antagonistic effects were
also greater for the response to ICI. The shorter duration lOP effect of ICI in the
contralateral eye was also antagonized by norBNl (Figure 18). Because there
was no difference in PD with ICI, norBNl data on PD is not shown.
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Figure 5. lOP dose response in the ipsilateral eye to the administration of
spiradoline. Spiradoline was administered topically and unilaterally in
NZW rabbits. Values represent the mean ± S.E. of the n number of
animals shown in the legend. *= p < 0.05, representing significant
difference from the control.
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Figure 6. lOP dose response in the contralateral eye to the administration of
spiradoline. Spiradoline was administered topically and unilaterally in
NZW rabbits. Values represent the mean ± S.E. of the n number of
animals shown in the legend. *= p < 0.05, representing significant




Figure 7. PD dose response in the ipsilateral eye to the administration of
spiradoline. Spiradoline was administered topically and unilaterally in
NZW rabbits. Values represent the mean ± S.E. of the n number of
animals shown in the legend. *= p < 0.05, representing significant




Figure 8. PD dose response in the contralateral eye to the administration of
spiradoline. Spiradoline was administered topically and unilaterally in
NZW rabbits. Values represent the mean ± S.E. of the n number of
animals shown In the legend. *= p < 0.05, representing significant
difference from the control.
AlOP(mmHg)
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Figure 9. lOP dose response in the ipsilateral eye to the administration of
ICI. ICI was administered topically and unilaterally in NZW rabbits.
Values represent the mean ± S.E. of the n number of animals shown in





Figure 10. lOP dose response in the contralateral eye to the administration of
ICI. ICI was administered topically and unilaterally in NZW rabbits.
Values represent the mean ± S.E. of the n number of animals shown In





Figure 11. PD dose response in the ipsilateral eye to the administration of
ICI. ICI was administered topically and unilaterally in NZW rabbits.
Values represent the mean ± S.E. of the n number of animals shown in





Figure 12. PD dose response in the contralateral eye to the administration of
ICI. ICI was administered topically and unilaterally in NZW rabbits.
Values represent the mean ± S.E. of the n number of animals shown in




Figure 13. Effect of norBNI pretreatment in the ipsilateral eye on spiradoline
induced changes in lOP. The administration of norBNI was topical and
bilateral. Values represent the mean ± S.E. of the n number of animals




Figure 14. Effect of norBNI pretreatment in the contralateral eye on
spiradoline induced changes in lOP. The administration of norBNI was
topical and bilateral. Values represent the mean ± S.E. of the n number
of animals shown in the legend. * = p < 0.05, representing significant




Figure 15. Effect of norBNI pretreatment in the ipsilateral eye on
spiradoline induced changes in PD. The administration of norBNI was
topical and bilateral. Values represent the mean ± S.E. of the n number
of animals shown in the legend. * = p < 0.05, representing significant




Figure 16. Effect of norBNI pretreatment in the contraiateral eye on
spiradoline induced changes in PD. The administration of norBNI was
topical and bilateral. Values represent the mean ± S.E. of the n number
of animals shown in the legend. :± p < 0.05, representing significant




Figure 17. Effect of norBNI pretreatment in the ipsilateral eye on
ICI-induced changes in lOP. The administration of norBNI was
topical and bilateral. Values represent the mean ± S.E. of the n number
of animals shown in the legend. * = p < 0.05, representing significant
difference from the control.
AIOP(mmHg)
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Figure 18. Effect of norBNI pretreatment in the contralateral eye on
ICI-induced changes in lOP. The administration of norBNI was
topical and bilateral. Values represent the mean ± S.E. of the n number
of animals shown in the legend. * = p < 0.05, representing significant
difference from the control.
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Prejunctional (Neuronal) Actions of Spiradoline and ICI
The effects of spiradoline and ICI were determined on norepinephrine
release from sympathetic neurons in the iris ciliary body to ascertain a possible
prejunctional (neuronal) site of action. The prejuctional (neuronal) actions of
spiradoline and ICI were studied in perfusion experiments using rabbit ICBs.
Electrically stimulated norepinephrine (NE) release was measured by liquid
scintillation counting of ^H-NE and values expressed as percent of control.
Spiradoline inhibited the release of NE from ICBs in a concentration-dependent
manner (Figure 19). The lowest concentration (10*^ M) was 68% of the control
but due to variability of the responses was not significantly different from the
control. The concentrations lO-® M and lO'® M produced responses that were
39% and 28% percent of the control, respectively. Both concentrations were
significantly different from the control (p<0.05).
ICI displayed a similar suppressive effect on the release of ^H-NE. Three
concentrations were used, lO'^, 10‘®, and IQ-® M. This kappa agonist produced
a dose-dependent inhibitory effect on the release of NE of 92%, 65%, and 43%
of control, respectively (Figure 20) The concentrations of lO ® and lO-^ M of ICI
produced significant inhibition. Both spiradoline (Figure 21a) and ICI (Figure
21b) were antagonized by norBNI at the two concentrations that significantly





Figure 19. Spiradoline-induced inhibition of 3H-NE release from electrically
stimulated ICBs. Values are represented as percent control, n=4.

























Figure 20. ICI-induced inhibition of 3H-NE release from electrically
stimulated ICBs. Values are represented as percent control. n=4.
*




Figure 21. Effect of norBNI pretreatment on 3H-NE release from electrically
stimulated ICBs. The antagonist alone, norBNI (10-5 M), was 88% of the
control (p>0.05). The effects of norBNI pretreatment on spiradoline- (a.)
and ICI-induced (b.) changes on 3H-NE release. Values are represented
as percent control. n=4. * = p < 0.05 when compared with control.
















Postjunctional (Ciliary Body) Actions of Spiradoline and ICI
Because kappa receptor agonists have been demonstrated to suppress
cAMP generated in a variety of tissues, this mechanism was investigated in the
iris ciliary body (ICB) of rabbits. Cyclic AMP accumulation in the iris ciliary body
was measured using radioimmunoassay. Isoproterenol (ISO) increased basal
levels of cAMP by 54%. A concentration-response curve was established using
the following amounts of spiradoline: 10‘3 M, lO'^ M, lO'^ M, and 10'6 M.
Spiradoline effectively decreased isoproterenol-stimulated cAMP levels in ICBs
(Figure 22). The ISO-stimulated level was decreased by lO'^ M, 10-4 M, lO'S M,
and 10-6 M doses of spiradoline by 53%, 39%, 36%, and 28%, respectively.
ICI 204,448 also displayed an ability to decrease ISO-stimulated cAMP
levels in ICBs (Figure 23). A concentration-response curve was generated with
several concentrations (10-5 M 10-® M, and lO-^ M) of ICI. These concentrations
did not display as clear cut a concentration dependent pattern as spiradoline
did. However, these responses were significantly different from the ISO-
stimulated levels of cAMP. Thus, ICI did have the ability to effectively lower the
levels of ISO-stimulated cAMP in ICBs.
Pretreatment with norBNI (10-^ M) inhibited the suppressive effects
of spiradoline and ICI on cAMP accumulation (Figure 24). A thirty minute
pretreatment of norBNI inhibited the spiradoline (10-^ M) -induced decreases of
cAMP accumulation in ICBs and the levels of cAMP were equivalent to the
levels of isoproterenol alone. ICI (10*5 M) was inhibited effectively by
pretreatment with norBNI; cAMP accumulation with the combination of nor-BNI
plus ICI plus ISO was not different from ISO alone.
50
Figure 22. Effects of spiradoline on ISO-stimulated cAMP accumulation in






Figure 23. Effects of ICI on ISO-stimulated cAMP accumulation in
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Figure 24. Effects of norBNI pretreatment on kappa agonist induced
suppression of ISO-stimulated cAMP accumulation in ICBs. Values are
represented pmol / mg protein. n=5. * = p < 0.05 when compared to ISO
alone. + = p < 0.05 when compared to SPIR/ICI + ISO.
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Atrial Natriuretic Peptide Release by Spiradoline and ICI
Atrial natriuretic peptide is, under normal circumstances, found in the
aqueous humor of NZW rabbits. The average control level for these
experiments was 7.5 ± 0.74 pg ANP / ml aqueous humor. A dose response for
ANP release was demonstrated for spiradoline (Figure 25). There was no
significant difference in ANP levels between the controls and 1 ^.g / 25 ^l
spiradoline. However, there was an increased response to 10 fxg / 25 nl and
100 ^g / 25 ^ll. The highest dose, 100 ^g / 25 ^1, increased the ANP level by
approximately 3-fold.
ICI 204,448, a kappa receptor agonist that has limited ability to the CNS,
showed minimal activity in increasing ANP levels in aqueous humor (Figure
26). Although there appeared to be a dose-related response, neither of the
responses were significantly different from the control, nor were the responses
different from one another.
In order to support the hypothesis that ANP was increased by way of
kappa receptors located within the anterior segment of the eye, norBNI was
applied 30 min prior to a challenge with the agonist. The highest dose (100 ^.g)
of spiradoline was used because it displayed the greatest increase in ANP
levels. There was a significant suppression of spiradoline-stimulated levels of
ANP after pretreatment with norBNI (Figure 27). The levels of ANP in aqueous
humor in response to norBNI plus spiradoline were not statistically different from
basal levels.
The data for norBNI effects on ANP levels with ICI are not shown
because there was no increase of ANP levels by ICI.
ANPLevels(pg/ml)
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Figure 25. Effect of spiradoline on ANP levels in aqueous humor. n=4.
*










Figure 27. Effect of norBNI pretreatment on spiradoline-induced changes in
ANP levels in aqueous humor. n=4. * = p < 0.05.
CHAPTER V
DISCUSSION
Medical treatment of glaucoma is focused on drugs that lower intraocular
pressure. Reduction of lOP by drugs has been demonstrated to protect against
further damage to the optic nerve head (Kass, 1989). To understand how drugs
alter lOP, it is helpful to understand the dynamics of the flow of aqueous humor
(ocular hydrodynamics). Aqueous humor is produced in the posterior chamber
of the anterior segment by the ciliary body and flows around the lens, through
the pupil, and into the anterior chamber. The nonpigmented ciliary epithelial
(NPCE) cells of the ciliary processes are the primary site of aqueous humor
formation. Receptors on NPCE cells and sympathetic nerve endings are targets
for drug-induced ocular hypotension. Aqueous humor leaves the anterior
chamber primarily through the trabecular meshwork into the venous system.
Increased lOP is caused generally by inadequate outflow of aqueous humor.
Increased lOP is one of the controllable risk factors in open-angle glaucoma.
The effects of several types of drugs, on ocular hydrodynamics, have
been demonstrated. The exact mechanism by which p-adrenergic antagonist
drugs lower intraocular pressure is not known, but p-adrenergic antagonists
decrease the production of aqueous humor (Dailey, 1982). Many types of
ocular hypotensive drugs are used in the treatment of glaucoma. Another drug
class used in the treatment of glaucoma is adrenergic agonists. These drugs
lower lOP through a complex series of interactions between a-adrenergic and
P-adrenergic stimulation (Sears, 1975). Alphag-adrenergic receptor stimulation
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causes a decrease in the production of aqueous humor by suppressing
aqueous humor formation and possibly by increasing uveoscleral outflow.
Prostaglandins are locally acting hormones which can either increase or
decrease lOP (Waitzman, 1967). At low concentrations, however, prostaglandin
Fza reduces lOP (Aim, 1995) by increasing uveoscleral outflow through the iris
root and ciliary body. This increase in uveoscleral outflow occurs either by
decreasing the extracellular matrix that surrounds the muscle bundles (Lutjen-
Drecoll, 1988) or by relaxing the ciliary musculature (Crawford, 1987).
Several subtypes of opioid receptors have been identified and
characterized in other tissues using selective radioactive ligands, selective
ligand alkylation protection studies and cross-tolerance studies. These different
receptors have proven to have dissimilar pharmacological properties. For
example, morphine, a p-opioid agonist, increases vasopressin release and
thereby inhibits diuresis, whereas a K-opioid agonist, such as U50,488,
decreases vasopressin release, thereby increasing diuresis (Leander, 1983).
The roles of three main subtypes of opioid receptors (5, p, and k) have not been
studied extensively for their effects on aqueous humor dynamics.
The effects of delta opioid agonists on ocular hydrodynamics have been
studied more recently (Wang, 1996). The d opioid receptor agonist, DPDPE,
was shown to lower lOP in NZW rabbits and both pre- and postjunctional sites
of action were investigated. The purpose of this study was to investigate
whether kappa receptor agonists can influence ocular hydrodynamics. The
current hypothesis tested the concept that relatively selective kappa agonists
can lower intraocular pressure (lOP). In this study, the effects of two kappa
opioid agonists, ICI 204,448, a highly selective K-receptor agonist with limited
ability to cross the blood-brain barrier, and spiradoline mesylate, were
evaluated and compared. The specific aims of this project were: 1) to
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characterize the activities of ICI and spiradoline in modifying the intraocular
pressure and pupil diameter in normal rabbits, 2) to investigate the potential
sites of action, i.e., pre- and postjunctional activities of kappa opioid receptors,
and 3) to determine the effect of kappa agonists on other neuroendocrine
mechanisms by assessing alterations of atrial natriuretic peptide levels in
aqueous humor.
With topical administration, both spiradoline and ICI significantly lowered
lOP when compared to the control (vehicle only) levels of lOP. ICI, compared to
spiradoline, was more effective at the highest dose (lOOpg/ 25|il) in the
ipsilateral eye. In the contralateral eye, the response to spiradoline was almost
as effective as in the ipsilateral eye. In this regard, the ocular hypotensive
response in the contralateral eye to a variety of drugs administered unilaterally,
has been speculated to occur as a result of redistribution of topically applied
drugs either to the contralateral eye (Burke, Crosson, and Potter, 1989) or the
brain . These data appear to support the redistribution of the drug to the
contralateral eye in the case of ICI because ICI has limited ability to cross the
pial/glial barrier, yet produces a contralateral response at the highest dose
tested. The pupil diameter data for the two drugs support the theory that some
drugs may have a central site of action. ICI had no effect on pupil diameter in
either the ipsilateral or the contralateral eye. In contrast, spiradoline caused
miosis and ocular hypotension in both eyes. The kappa opioid antagonist,
norBNI, successfully inhibited the effects of spiradoline and ICI on lOP and also
antagonized the miotic effects of spiradoline on the iris. However, the inhibition
by norBNI was greater in the lOP experiments when the agonist was ICI.
Although norBNI inhibited the effects of spiradoline on lOP, the inhibition was
less pronounced.
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Thus, in this study relatively selective opioid agonists, spiradoline and
ICI, have been shown to lower lOP in the eyes of rabbits. It was assumed that
this ocular hypotensive response to opioids could be mediated, in part, by
prejunctional (neuronal) inhibition of norepinephrine secretion from sympathetic
nerves in the iris ciliary body. Preiously, it has been shown that opioid ligands
regulate the release of neurotransmitters in the central and in the peripheral
nervous system by activating presynaptic/prejunctional opioid receptors
(Jhamandas, 1977; Oron, 1991; and Werling, 1987). Studies have revealed
that there are differences among the species in the inhibitory action of opioid
receptors in brain cortex slices. In rabbit brain cortex, this opioid action is
mediated by the kappa receptor (Limberger, 1986). Experiments were
performed to determine if kappa receptors are present on ocular sympathetic
nerves.
It’s shown by the data generated in this study, that spiradoline and ICI
inhibited ^H-NE release from sympathetic neurons of rabbit iris ciliary body in a
dose-dependent manner. Spiradoline appeared to be more potent than ICI in
its ability to inhibit norepinephrine release. In the experiments to confirm that
this effect was indeed mediated by kappa opioid receptors, again pretreatment
with the relatively selective kappa receptor antagonist norBNI was utilized.
The inhibitory action of norBNI demonstrated that both spiradoline and ICI act,
in part, on peripheral sympathetic neurons to depress lOP by suppressing NE
release. Several molecular mechanisms have been suggested to explain the
inhibitory influence of opioid agonists on neurotransmitter release. Opioid
agonists have been shown to block calcium entry through voltage-operated
calcium channels (Hescheler, 1987; and Henderson, 1990), to promote
hyperpolarization by activating potassium channels (North, 1987), and to inhibit
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adenylate cyclase (Attali, 1989). Any one of these effects have the potential to
suppress transmitter release from ocular sympathetic nerves.
Because opioid receptors of all classes have been shown to be
negatively coupled to adenylate cyclase, spiradoline and ICI were evaluated for
their ability to inhibit ISO-stimulated cAMP accumulation in the rabbit ICB.
Because the phosphodiesterase inhibitor IBMX was included in the incubation
medium, the inhibition was not caused by increased degradation of cAMP, but
by suppression of formation. The inhibition observed in the ICB, occurred in the
presence of stimulation of adenylate cyclase by isoproterenol and was
abolished by the antagonist, norBNI. In vitro, tissues lining the anterior
chamber, such as the cornea, iris, and sclera-trabecular tissue make cAMP in
response to various agonists and cAMP is release into the incubation media
(Neufeld, 1974). Drugs, such as 0.2 agonists and p-adrenoceptor antagonists,
that depress cAMP formation in ocular tissues, can lower lOP. Kappa agonists,
like the prior drugs, could possibly lower lOP by suppressing cAMP formation as
well.
Opioids are known to control water balance in animals as well as in man.
The diuretic effect is apparently dependent on the receptor specificity of the
opioid used. As alluded to previously, K-opioid receptor agonists cause
pronounced diuresis (Leander, 1983). If kappa opioid receptor activation
causes increases in fluid excretion by the kidney, then it is possible that these
receptors play a role in the flow of aqueous humor within the anterior chamber
of the eye. This action may involve a kappa agonist-induced increase in atrial
natriuretic peptide (ANP) levels in aqueous humor. Previously, it has been
demonstrated that ANP is present in aqueous humor of rabbit (Femandez-
Durango, 1990) and that ANP can significantly decrease lOP (Sugrue, 1986).
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Moreover, nonpigmented ciliary epithelial cells have the genetic capacity to
synthesize natriuretic peptides.
In the present study, ANP was increased dose dependently by
spiradoline in concomitantly with a decrease of lOP. However, ICI had no effect
on ANP levels in aqueous humor. These data support the earlier findings that
central opioid receptors may be involved in the secretion of ANP (Chen, 1989;
Vollmar, 1987). The kappa receptor antagonist, norBNI, inhibited the response
of spiradoline on ANP at the highest dose (100 pg/ 25 pi) used. Previously,
experimentation has shown previously that rabbit eyes with experimentally-
induced glaucoma have a significant reduction in the number of ANP binding
sites in ciliary processes compared to normal eyes and that activation of ANP
receptors in ciliary processes may play a role in regulating lOP (Fernandez-
Durango, 1991). Some of the ocular hydrodynamic activity of kappa receptor
agonists could be mediated indirectly by releasing ANP.
Receptor binding studies have provided evidence for the existence of
multiple kappa receptor sites in human brain (Pfeiffer, 1981), guinea pig spinal
cord (Attali, 1982), bovine adrenal medulla (Castanas, 1985), and rat brain
(Zukin, 1988). The selective kappa opioid receptor agonist, bremazocine has
been shown to have a higher affinity for K-2 sites (Zukin, 1988). In similar
experiments from our laboratory, bremazocine has proven to be more active
than both spiradoline and ICI in lowering lOP. Because the kappa antagonist,
norBNI, has been shown to be selective for kappa-1 receptors, this may mean
that spiradoline and ICI act more so on kappa-1 receptors than kappa-2.
Additional studies will be required to delineate the role of kappa receptor
subtypes in modulating ocular hydrodynamics.
CHAPTER VI
SUMMARY AND CONCLUSIONS
In summary, this research project investigated the mechanisms by which
spiradoline and ICI influence ocular hydrodynamics. Spiradoline:
1. reduced lOP in a dose-dependent manner,
2. caused a miotic affect in pupil diameter,
3. decreased cAMP accumulation in ICBs in a dose-dependent
manner,
4. increased levels of ANP in aqueous humor, and
5. inhibited ^H-NE release from perfused ICBs.
The kappa agonist ICI, which has limited access to the CNS,:
1. reduced lOP but only at the highest dose tested,
2. had no effect on pupil diameter,
3. decreased cAMP accumulation in ICBs,
4. had no effect on ANP levels in aqueous humor, and
5. inhibited ^H-NE release from perfused ICBs.
These data suggest some of the possible mechanisms by which kappa
opioid agonist lower lOP. In conclusion, the reduction of lOP in normal NZW
rabbits by the kappa opioid agonists, ICI and spiradoline, is mediated by kappa
opioid receptors in the eye based upon antagonism of the responses by norBNI.
The effect of spiradoline on pupil diameter indicates that this kappa agonist
activates receptors in the eye and/or in the CNS. The inhibition of ISO-
stimulated cAMP accumulation in ICBs suggests a postjunctional site of action
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of these kappa agonists in the anterior segment of the eye. The increase in
ANP levels in aqueous humor by spiradoline suggests a role for ANP in
lowering lOP, which may be mediated through receptors in the CNS. Lastly, the
inhibition of ^H-NE release in perfused rabbit ICBs indicated a prejunctional site
of action for kappa opioid agonists on receptors on peripheral sympathetic
neurons.
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